NCT06663787Active, not recruiting
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer. The updated data of the CLEOPATRA trial showed significant Kaplan-Meier curves, suggesting the potential for a cure. However, the efficacy of maintenance therapy in long-term responders remains unexplored. This study will assess MRD in unresectable HER2-positive breast cancer cases with long-term response using the Signatera™ ctDNA assay, which could contribute to future treatment strategy development.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 24 Oct 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Nagoya City University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06663787
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Apr 2024 to the primary completion date, 31 Dec 2026
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who were deemed inappropriate as research subjects based on the physician's judgment, such as those possibly receiving inappropriate treatment.
Who the study is looking for
- HER2 + metastatic breast cancer
- Pre / post menopausal
- Previously treated with anti-HER2 therapy
- Continuing CR or PR for more than 2 year
Age in the registry: 20 years to - · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aichi Cancer Center Coordinator of this site? Confirm its status | Nagoya | Japan | Unknown status |
| Nagoya City University Coordinator of this site? Confirm its status | Nagoya | Japan | Unknown status |
| The Cancer Institute Hospital of Japanese Foundation for Cancer Research Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| Natera Coordinator of this site? Confirm its status | San Carlos | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.